International Society

Altavair Appoints Head of Marketing

Retrieved on: 
Monday, June 24, 2024

Altavair Limited (“Altavair”), a global aviation asset manager, is pleased to announce the appointment of Frank O’Hagan as the company's Head of Marketing.

Key Points: 
  • Altavair Limited (“Altavair”), a global aviation asset manager, is pleased to announce the appointment of Frank O’Hagan as the company's Head of Marketing.
  • Prior to joining Altavair, he served as Head of Marketing – Global Leasing with Bank of America Leasing Ireland, having previously held senior positions with ASL Aviation and Ryanair.
  • In his new role at Altavair, Mr. O’Hagan will have responsibility for managing the Marketing and Trading functions, originating new business, marketing portfolio aircraft, and further developing airline client relationships globally.
  • “I am excited about joining the Altavair team and helping them grow the business into the future,” says Frank O’Hagan, Head of Marketing with Altavair.

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Retrieved on: 
Sunday, June 23, 2024

Takeda ( TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder.
  • ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating.
  • These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand.
  • Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024.

Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion

Retrieved on: 
Friday, June 21, 2024

Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38th International Congress of the International Society of Blood Transfusion (ISBT), taking place in Barcelona, Spain, from June 23 through June 27.
  • Transfusion medicine experts and professionals from around the world attend the ISBT Congress.
  • The following is a list of selected presentations and abstracts of interest for Cerus.
  • The full program of Cerus-related abstracts can be found at the following link: https://interceptbloodsystem.com/sites/default/files/resources/2024_isbt....

Seaport Therapeutics Appoints Seasoned Executives to Management Team

Retrieved on: 
Tuesday, June 18, 2024

“We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport.

Key Points: 
  • “We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport.
  • Most recently, she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and diagnostics for neurodegenerative diseases.
  • “I am humbled and thrilled to be joining the team at Seaport,” said Ms. Gladstein.
  • “This is a team with an incredible track record of achievement and an unwavering commitment to advancing innovative therapeutics for patients.

PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team

Retrieved on: 
Tuesday, June 18, 2024

Most recently, she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and diagnostics for neurodegenerative diseases.

Key Points: 
  • Most recently, she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and diagnostics for neurodegenerative diseases.
  • Most recently, she was the Group General Counsel at APRINOIA Therapeutics, a clinical-stage company developing therapeutics and diagnostics for neurodegenerative diseases.
  • “I am humbled and thrilled to be joining the team at Seaport,” said Ms. Gladstein.
  • “This is a team with an incredible track record of achievement and an unwavering commitment to advancing innovative therapeutics for patients.

Be Your Possible’s Third Annual Run for Research Unlocks $500,000 Donation for Medical Research From Sermo

Retrieved on: 
Monday, June 17, 2024

Run for Research , an annual global connected run to raise money for life-saving medical research, proudly announces a $500,000 donation to support medical research after reaching a milestone 10,000+ registrants for the event on June 9th.

Key Points: 
  • Run for Research , an annual global connected run to raise money for life-saving medical research, proudly announces a $500,000 donation to support medical research after reaching a milestone 10,000+ registrants for the event on June 9th.
  • This past Sunday, Run for Research activated 10,160 total runners of which over 9,000 physician runners, spanning 86 countries and over 71,000km.
  • “I am incredibly proud of how Run for Research has united people globally in support of critical medical research,” said Peter Kirk, CEO of Sermo and Founder of Run for Research.
  • The organization was founded in 2022 launching its first initiative, Run for Research (formally known as Run with Peter), a global movement mobilizing thousands to run in support of medical research.

ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment

Retrieved on: 
Friday, June 21, 2024

Among these recommendations, strong endorsements advocate for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B, underscoring a paradigm shift in clinical practice.

Key Points: 
  • Among these recommendations, strong endorsements advocate for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B, underscoring a paradigm shift in clinical practice.
  • Recognizing that hemophilia is a rare and complex disease that poses challenges for guideline development and implementation, the new guideline contributes valuable insights into the evolving hemophilia treatment landscape.
  • "With hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight, yet highlighting the importance of making treatment decisions consistent with patients' individual risks, values, and preferences," stated Suely M. Rezende, M.D., Ph.D., Chair of the ISTH Hemophilia Guideline Panel.
  • By continuously updating and complementing this guideline, the ISTH aims to drive innovation and enhance outcomes for individuals living with hemophilia worldwide.

ISTH announces launch of new global education initiative in factor XI/XIa inhibition

Retrieved on: 
Friday, June 21, 2024

BANGKOK, June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis, announces the official launch of new education titled "ISTH Emerging Therapies in Thrombosis—Factor XI/XIa Inhibitors". The organization is embarking on a comprehensive, globally relevant educational initiative to increase clinician awareness of factor XI (FXI) inhibition and how it might lead to the development of safer anticoagulation therapy.

Key Points: 
  • The organization is embarking on a comprehensive, globally relevant educational initiative to increase clinician awareness of factor XI (FXI) inhibition and how it might lead to the development of safer anticoagulation therapy.
  • In early 2023, the ISTH organized the multi-disciplinary, international Factor XI/XIa Educational Steering Committee, a group of world-renowned experts led by Jeff Weitz, MD, to survey a sample of the multi-disciplinary target audiences for this education.
  • This 20-minute lecture will be recorded and broadcast in the ISTH Academy booth throughout the meeting and shared on the ISTH Academy after the Congress.
  • "Launching the factor XI/XIa educational roadmap in Bangkok is an exciting opportunity to kick off this global education initiative," said Weitz, the ISTH's recently elected Secretary General for 2024-2028 term.

ISTH Releases Evidence-Based Clinical Practice Guideline for Hemophilia Treatment

Retrieved on: 
Friday, June 21, 2024

Among these recommendations, strong endorsements advocate for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B, underscoring a paradigm shift in clinical practice.

Key Points: 
  • Among these recommendations, strong endorsements advocate for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B, underscoring a paradigm shift in clinical practice.
  • Recognizing that hemophilia is a rare and complex disease that poses challenges for guideline development and implementation, the new guideline contributes valuable insights into the evolving hemophilia treatment landscape.
  • "With hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight, yet highlighting the importance of making treatment decisions consistent with patients' individual risks, values, and preferences," stated Suely M. Rezende, M.D., Ph.D., Chair of the ISTH Hemophilia Guideline Panel.
  • By continuously updating and complementing this guideline, the ISTH aims to drive innovation and enhance outcomes for individuals living with hemophilia worldwide.

ISTH announces launch of new global education initiative in factor XI/XIa inhibition

Retrieved on: 
Friday, June 21, 2024

BANGKOK, June 21, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of conditions related to thrombosis and hemostasis, announces the official launch of new education titled "ISTH Emerging Therapies in Thrombosis—Factor XI/XIa Inhibitors". The organization is embarking on a comprehensive, globally relevant educational initiative to increase clinician awareness of factor XI (FXI) inhibition and how it might lead to the development of safer anticoagulation therapy.

Key Points: 
  • The organization is embarking on a comprehensive, globally relevant educational initiative to increase clinician awareness of factor XI (FXI) inhibition and how it might lead to the development of safer anticoagulation therapy.
  • In early 2023, the ISTH organized the multi-disciplinary, international Factor XI/XIa Educational Steering Committee, a group of world-renowned experts led by Jeff Weitz, MD, to survey a sample of the multi-disciplinary target audiences for this education.
  • This 20-minute lecture will be recorded and broadcast in the ISTH Academy booth throughout the meeting and shared on the ISTH Academy after the Congress.
  • "Launching the factor XI/XIa educational roadmap in Bangkok is an exciting opportunity to kick off this global education initiative," said Weitz, the ISTH's recently elected Secretary General for 2024-2028 term.